JBIO
The table below shows Jade Biosciences, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$94.69M | -$71.20M | -$56.78M | -$39.12M | -$27.40M | -$7.86M |
| Capital expenditure | $196.00K | - | $142.00K | $195.00K | $181.00K | - |
| Investing cash flow | -$247.01M | $56.03M | $11.88M | $6.93M | -$113.43M | - |
| Dividends paid | - | - | - | - | - |
Jade Biosciences, Inc. reported operating cash flow of -$94.69M for fiscal year 2025. That is down 33.0% from -$71.20M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$7.86M (FY 2020) to -$94.69M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $360.77M | $25.43M | $46.00M | $396.00K | $190.46M | $8.92M |